Phase 3 Readout

COGT: Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S

Name: Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S
Start: 2030-01-01
End: 2030-01-01

January 1, 2030 · cgt9486. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2030
Company: Cogent Biosciences, Inc. (COGT)
Drug: cgt9486

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S

January 1, 2030

COGT overview →

Company: Cogent Biosciences, Inc. (COGT)
Drug: cgt9486
Indication: Metastatic Cancer; Advanced Gastrointestinal Stromal Tumors